Derivation and validation of a risk classification tree for patients with synovial sarcoma

Background Synovial sarcoma (SS) accounts for 8%–10% of all soft‐tissue sarcomas. Clinical presentation and outcomes vary, yet discrete risk groups based on validated prognostic indices are not defined for the full spectrum of patients with SS. Methods We performed a retrospective cohort study using...

Full description

Saved in:
Bibliographic Details
Published in:Cancer medicine (Malden, MA) MA), 2023-01, Vol.12 (1), p.170-178
Main Authors: Neel, Dylan V., Ma, Clement, Collins, Natalie B., Hornick, Jason L., Demetri, George D., Shulman, David S.
Format: Article
Language:English
Subjects:
Adult
Age
Cancer therapies
Chemotherapy
Classification
Diagnosis
Epidemiology
Hispanic Americans
Histology
Humans
Medical prognosis
Metastasis
oncology
Patients
Prognosis
prognostic factors
Radiation
Retrospective Studies
Risk Factors
Risk groups
risk‐stratification
Sarcoma
Sarcoma - pathology
Sarcoma, Synovial - diagnosis
Sarcoma, Synovial - therapy
SEER Program
Sex
Survival
Synovial sarcoma
Tumors
Variables
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Synovial sarcoma (SS) accounts for 8%–10% of all soft‐tissue sarcomas. Clinical presentation and outcomes vary, yet discrete risk groups based on validated prognostic indices are not defined for the full spectrum of patients with SS. Methods We performed a retrospective cohort study using data from the SEER (surveillance, epidemiology, and end results program) database of SS patients who were
ISSN:2045-7634
2045-7634
DOI:10.1002/cam4.4909